Pseudomonas Species

You probably have not heard much about Pseudomonas in the gut. It is not a household name like E. coli, and most routine stool tests do not even look for it. But when researchers do measure it, higher levels of these opportunistic bacteria show up in people with Crohn's disease, ulcerative colitis, certain liver conditions, and in people carrying antibiotic-resistant strains they did not know were there.

This test uses PCR (polymerase chain reaction), a laboratory method that copies and identifies tiny amounts of bacterial DNA, to look for Pseudomonas genetic material in your stool. It is a research-grade window into one slice of your gut microbiome, not an established diagnostic test, and the results are best read as a clue about gut ecology rather than a verdict on any single disease. A 2025 international consensus statement on microbiome testing cautions that single-organism PCR should not be treated as a substitute for full microbiome profiling, which reinforces why this result is exploratory.

What This Test Actually Measures

Stool PCR for Pseudomonas species detects and quantifies bacterial DNA, usually by amplifying the 16S rRNA gene (a stretch of genetic code that almost all bacteria share but that differs slightly between species) or a Pseudomonas-specific sequence. The reading is normalized against total bacterial DNA in the sample, so it reflects how abundant these organisms are relative to the rest of your gut community.

Pseudomonas is a genus of bacteria, not a single organism. The most clinically familiar member is Pseudomonas aeruginosa, a known opportunistic pathogen. Other members, like Pseudomonas fluorescens, are usually low-abundance colonizers with more ambiguous health significance, though about half of people with Crohn's disease develop antibodies to P. fluorescens, hinting at an immune interaction that is still being worked out. Because most assays at the genus level cannot fully separate these species, a positive signal is a starting point for investigation, not a diagnosis.

Inflammatory Bowel Disease

The strongest disease link in the human literature is with inflammatory bowel disease, especially Crohn's disease. In a study that included 120 patients with inflammatory bowel disease, 28 non-IBD inflammation controls, and 67 healthy controls, Pseudomonas species were significantly more abundant in the gut mucosa of IBD patients than in controls, and this finding held independent of disease severity, biopsy findings, medications, and other clinical variables.

In children with suspected Crohn's disease, 58% (18 of 32) had ileal biopsies that tested positive for Pseudomonas by PCR, compared with 33% (12 of 36) of children without inflammatory bowel disease. Pseudomonas diversity was also lower in Crohn's disease, suggesting a narrower set of strains was colonizing the inflamed tissue. Interestingly, in that same pediatric cohort P. aeruginosa specifically was identified only in non-IBD controls and not in the Crohn's disease group, which is a reminder that genus-level findings do not always point to the same species.

Why the Stool Signal Can Disagree With the Mucosal Signal

Here is a finding that looks contradictory at first. The same inflammatory bowel disease study showed Pseudomonas was high in the gut mucosa but not consistently elevated in matched stool samples from the same people, especially in Crohn's disease. So how can stool levels be a useful clue if the bacteria can be hiding on the gut wall?

The resolution is that stool PCR captures the luminal population (organisms floating in the gut contents) rather than the mucosal population (organisms physically attached to the gut lining). A high stool reading is a real signal of bloom or overgrowth. A low or normal stool reading does not rule out mucosa-predominant colonization. This is not a paradox; it is two different sampling windows on the same gut, and you need to interpret a negative stool result with that limitation in mind.

Liver and Bile-Duct Conditions

In infants with biliary atresia (a rare condition in which bile ducts are damaged or blocked from birth), stool microbiome analysis showed lower Bifidobacterium and higher Enterococcus, Clostridium, Fusobacterium, and Pseudomonas compared with healthy infants. Higher post-surgical gut diversity that included these opportunistic taxa was linked to worse outcomes at six months, although in that analysis the specific genera most strongly tied to unfavorable outcomes were Streptococcus and Fusobacterium rather than Pseudomonas itself.

In adults, a study of Egyptian participants found that the gut of people with hepatocellular carcinoma was enriched in specific species, including Pseudomonas aeruginosa, compared with healthy controls and people with hepatitis C cirrhosis. This is an association in a single cohort, not proof that Pseudomonas causes liver cancer, and it should be read as part of a broader dysbiotic pattern. Other hepatocellular carcinoma microbiome studies have not consistently identified Pseudomonas as a key enriched taxon, so the finding needs replication.

Carriage of Antibiotic-Resistant Strains

Pseudomonas aeruginosa picked up from stool can carry resistance genes that matter clinically. In a study of people with chronic kidney disease in Cameroon, fecal carriage of Pseudomonas aeruginosa was about 9%, and among those isolates, roughly 86% harbored at least one extended-spectrum beta-lactamase (ESBL) gene, which is a marker for resistance to many common antibiotics.

Roughly 74% of these isolates were multidrug-resistant. Similar patterns appeared in stool isolates from people living with HIV in Nigeria, where a substantial share of Pseudomonas isolates produced ESBL enzymes. These studies are not direct evidence that Pseudomonas carriage will harm a healthy person, but they show why detection in a high-risk setting can be useful clinical information.

Bloodstream Infection in High-Risk Cohorts

In adults with acute myeloid leukemia (a cancer of blood-forming cells) who developed bloodstream infections, the relative abundance of Pseudomonas aeruginosa in stool was significantly higher in those whose blood cultures grew Pseudomonas than in those whose infections came from other organisms. Specialized droplet digital PCR confirmed the bacteria at the species level in stool, suggesting the gut acted as the source reservoir.

This is not a screening use case for the general public. It illustrates that for severely immunocompromised people, gut Pseudomonas is sometimes the first warning sign of an organism that can move from the intestine into the blood.

Why One Reading Is Not Enough

Single stool PCR readings can vary a lot. Your gut community shifts with diet, recent antibiotics, illness, and even sampling within the stool itself. A snapshot might catch a transient bloom or miss a low-grade colonization that returns the following week. For a research-grade marker like this, the trajectory is more informative than any one number.

There is no established evidence-based retesting schedule for single-taxon stool PCR, and international microbiome testing guidance does not endorse routine serial testing of individual organisms. If you and your clinician decide to track this marker over time, repeating it a few months after meaningful changes to diet, supplements, or antibiotic use (and comparing two or three readings before treating any single result as meaningful) is a reasonable approach rather than a guideline-backed protocol.

When Results Can Be Misleading

• Stool only sees the lumen: the most important confounder is sampling. Pseudomonas can colonize the gut lining in inflammatory bowel disease without showing up in matched stool, so a negative result does not exclude mucosal colonization or active gut inflammation.
• Genus-level signal hides species differences: a positive reading does not tell you whether you are carrying a benign environmental species or Pseudomonas aeruginosa. Follow-up testing or culture is often needed to clarify which member of the genus is present.
• Recent antibiotics shift the read: any antibiotic in the weeks before the test can dramatically reshape your gut microbiome, suppressing or selecting for Pseudomonas in ways that do not reflect your normal state.
• PCR detects DNA, not living bacteria: the test cannot distinguish viable organisms from dead bacterial DNA, and stool matrices can also contain compounds that interfere with the PCR reaction itself.

Decision Pathway for an Unexpected Result

If your reading is unexpectedly high, think in terms of pattern, not panic. The most useful next steps depend on the rest of your picture. If you have ongoing gastrointestinal symptoms, the combination of high Pseudomonas with elevated calprotectin (a marker of gut inflammation) or other dysbiosis signals strengthens the case for a gastroenterology workup, which may include endoscopy with mucosal sampling that this test cannot replace.

If you are otherwise well, a single elevated reading is more likely a snapshot of microbial flux than a hidden infection. Retest in a few months, ideally well away from any antibiotic course or acute illness. If you are immunocompromised, recovering from recent surgery, or have known chronic conditions like inflammatory bowel disease or chronic kidney disease, share the result with a clinician who can decide whether to confirm with stool culture, look for resistance genes, or pair it with companion tests like calprotectin or a broader microbiome panel.